The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity

Life Sciences

Volumn 87, Issue 3-4, 2010, Pages 126-132

  Wójcicka, Grazyna ^a   Jamroz Wiśniewska, Anna ^a   Marciniak, Andrzej ^a   Łowicka, Ewelina ^a   Bełtowski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Diabetes; Glibenclamide; Glimepiride; Paraoxonase; Platelet activating factor acetylohydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 4 HYDROXYNONENAL; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; CHOLESTEROL; GLIBENCLAMIDE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN; MALONALDEHYDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; GLUCOSE BLOOD LEVEL; LIPID PEROXIDATION; LIVER; LIVER FUNCTION; LIVER WEIGHT; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SPECTROPHOTOMETRY; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, EXPERIMENTAL; GLYBURIDE; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIVER; MALE; RATS; RATS, WISTAR; SPECTROPHOTOMETRY; STREPTOZOCIN; SULFONYLUREA COMPOUNDS;

RATTUS;

EID: 77954313000     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.05.018     Document Type: Article

References (60)

1. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology 1995, 15(11):1812-1818.
2. Ambrosio G., Oriente A., Napoli C., Palumbo G., Chiariello P., Marone G., Condorelli M., Chiariello M., Triggiani M. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. The Journal of Clinical Investigation 1994, 93(6):2408-2416.
3. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine 1999, 26(7-8):892-904.
4. Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., Durrington P.N. Serum paraoxonase after myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 1999, 19(2):330-335.
5. Bakillah A. Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects. Clinical Chemistry and Laboratory Medicine 2009, 47(1):60-69.
6. Barish G.D. Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity. The Journal of Nutrition 2006, 36(3):690-694.
7. Beltowski J., Wójcicka G., Jamroz-Wiśniewska A., Borkowska E., Marciniak A. Antioxidant treatment normalizes nitric oxide production, renal sodium handling and blood pressure in experimental hyperleptinemia. Life Sciences 2005, 77(15):1855-1868.
8. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Analytical Biochemistry 1996, 239(1):70-76.
9. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. The Journal of Biological Chemistry 2002, 77(6):4301-4308.
10. Elmalí E., Altan N., Bukan N. Effect of the sulphonylurea glibenclamide on liver and kidney antioxidant enzymes in streptozocin-induced diabetic rats. Drugs in R&D 2004, 5(4):203-208.
11. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods in Enzymology 1990, 186:407-421.
12. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 2003, 52(1):1-8.
13. Fan Y., Wang Y., Tang Z., Zhang H., Qin X., Zhu Y., Guan Y., Wang X., Staels B., Chien S., Wang N. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28(2):315-321.
14. Farrar N.S., Chambers N.J., Carlsson A.R., Denyer G., Johnston G.A. Effect of a series of novel sulphonylthioureas on glucose tolerance in the obese fa/fa Zucker rat. Clinical and Experimental Pharmacology & Physiology 2001, 28(5-6):386-391.
15. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139(2):307-315.
16. Ferré N., Camps J., Prats E., Vilella E., Paul A., Figuera L., et al. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry 2002, 48(2):261-268.
17. Ferretti G., Bacchetti T., Marchionni C., Caldarelli L., Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetologica 2001, 38(4):163-169.
18. Fuhrman B., Volkova N., Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005, 180(1):55-61.
19. Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. The Journal of Biological Chemistry 2005, 280(25):23653-23659.
20. Gonzalvo M.C., Gil F., Hernandez A.F., Rodrigo L., Villanueva E., Pla A. Human liver paraoxonase (PON1): Subcellular distribution and characterization. Journal of Biochemical and Molecular Toxicology 1998, 12(1):61-69.
21. Gouédard C., Koum-Besson N., Barouki R., Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molecular Pharmacology 2003, 63(4):945-956.
22. Gregorio F., Ambrosi F., Cristallini S., Filipponi P., Santeusanio F. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetologica 1996, 33(1):25-29.
23. Hardardóttir I., Grünfeld C., Feingold K.R. Effects of endotoxin and cytokines on lipid metabolism. Current Opinion in Lipidology 1994, 5(3):207-215.
24. Hoang A., Murphy A.J., Coughlan M.T., Thomas M.C., Forbes J.M., O'Brien R., et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007, 50(8):1770-1779.
25. Hong S.C., Zhao S.P., Wu Z.H. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. Journal of Cardiovascular Pharmacology 2006, 47(1):77-81.
26. Ikeda Y., Suehiro T., Arii K., Kumon Y., Hashimoto K. High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism 2008, 57(12):1725-1732.
27. Karabina S.A., Lehner A.N., Frank E., Parthasarathy S., Santanam N. Oxidative inactivation of paraoxonase - implications in diabetes mellitus and atherosclerosis. Biochimica et Biophysica Acta 2005, 1725(2):213-221.
28. Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. Journal of Lipids Research 2004, 45(7):1169-1196.
29. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Current Diabetes Reports 2008, 8(1):51-59.
30. Kumon Y., Suehiro T., Ikeda Y., Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sciences 2003, 73(22):2807-2815.
31. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. The Journal of Biological Chemistry 1951, 193(1):265-275.
32. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139(2):341-349.
33. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters 1991, 286(1-2):152-154.
34. MacRitchie A.N., Gardner A.A., Prescott S.M., Stafforini D.M. Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation. The FASEB Journal 2007, 21(4):1164-1176.
35. Marsillach J., Camps J., Ferré N., Beltran R., Rull A., Mackness B., et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 2009, 9:3.
36. Memon R.A., Fuller J., Moser A.H., Feingold K.R., Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. The American Journal of Physiology 1999, 277(1 Pt 2):R94-R103.
37. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radical Biology & Medicine 2006, 41(7):1031-1040.
38. Nguyen S.D., Sok D.E. Effect of 3, 4-dihydroxyphenylalanine on Cu(2+)-induced inactivation of HDL-associated paraoxonasel and oxidation of HDL; inactivation of paraoxonasel activity independent of HDL lipid oxidation. Free Radical Biology & Medicine 2004, 38(9):969-976.
39. Nguyen S.D., Sok D.E. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radical Research 2003, 37(12):1319-1330. Dec.
40. Patel B.N., Mackness M.I., Harty D.W., Arrol S., Boot-Handford R.P., Durrington P.N. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochimica et Biophysica Acta 1990, 1035(1):113-116.
41. Pond A.L., Chambers H.W., Coyne C.P., Chambers J.E. Purification of two rat hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon. The Journal of Pharmacology and Experimental Therapeutics 1998, 286(3):1404-1411.
42. Pritchard P.H. The degradation of platelet-activating factor by high-density lipoprotein in rat plasma. Effect of ethynyloestradiol administration. Biochememical Journal 1987, 246(3):791-794.
43. Rosenblat M., Karry R., Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006, 187(1):74-81.
44. Rozenberg O., Shih D.M., Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23(3):461-467.
45. Rozenberg O., Shiner M., Aviram M., Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radical Biology & Medicine 2008, 44(11):1951-1959.
46. Sagara M., Satoh J., Zhu X.P., Takahashi K., Fukuzawa M., Muto G., Muto Y., Toyota T. Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats. Clinical Immunology and Immunopathology 1994, 71(3):333-337.
47. Sato J., Ohsawa I., Oshida Y., Sato Y., Sakamoto N. Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabetes Research and Clinical Practice 1993, 22(1):3-9.
48. Schiekofer S., Rudofsky G., Andrassy M., Schneider J., Chen J., Isermann B., et al. Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. Diabetes, Obesity & Metabolism 2003, 5(4):251-261.
49. Shakuto S., Oshima K., Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2005, 182(2):209-217.
50. Smits P., Bijlstra P.J., Russel F.G., Lutterman J.A., Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Research and Clinical Practice 1996, 31:S55-S59. Suppl.
51. Trapali M., Mavri-Vavayanni M., Siafaka-Kapadai A. PAF-acetylhydrolase activity and PAF levels in pancreas and plasma of well-fed, diabetic and fasted rat. Life Sciences 1996, 59(10):849-857.
52. Tselepis A.D., John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis 2002, Suppl. 3(4):57-68.
53. Tsubouchi H., Inoguchi T., Inuo M., Kakimoto M., Sonta T., Sonoda N., et al. Sulfonylurea as well as elevated glucose levels stimulate reactive oxygen species production in the pancreatic beta-cell line, MIN6-a role of NAD(P)H oxidase in beta-cells. Biochemical and Biophysical Research Communications 2005, 326(1):60-65.
54. Tsunekawa T., Hayashi T., Suzuki Y., Matsui-Hirai H., Kano H., Fukatsu A., Nomura N., Miyazaki A., Iguchi A. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003, 26(1):285-289.
55. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106(4):484-490.
56. Ueba H., Kuroki M., Hashimoto S., Umemoto T., Yasu T., Ishikawa S.E., et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 2005, 183(1):35-39.
57. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
58. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. The Journal of Clinical Investigation 1995, 96(6):2758-2767.
59. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001, 103(18):2283-2288.
60. van Wijk J., Coll B., Cabezas M.C., Koning E., Camps J., Mackness B., et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clinical and Experimental Pharmacology & Physiology 2006, 33(12):1134-1137.